Novel Therapy for Pediatric Leukemia Patients with NUP98 Translocations |
The Regents of the University of Michigan / Jolanta Grembecka, PhD |
Reach Grants |
2022 |
Michigan |
Preclinical Development of Targeted Therapy for Neuroblastoma with ALK and CDK4/6 Dual Pathway Inhibition
|
Children’s Hospital of Philadelphia / Yael Mossé, MD |
Reach Grants |
2013 |
Pennsylvania |
Immuno-therapeutic Targeting of CD56 in CBA2T3/GLIS2-AML in Children |
Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD/PhD |
Reach Grants |
2018 |
Washington |
Epigenomics of High Risk Pediatric T Cell Leukemia |
New York University School of Medicine / Iannis Aifantis, PhD |
Reach Grants |
2013 |
New York |
Development of a Pharmacodynamic Marker of EWS-FLI1 Activity to Aid in the Clinical Translation of Targeted Therapies for Ewing sarcoma |
Van Andel Research Institute / Patrick Grohar, MD, PhD |
Reach Grants |
2013 |
Michigan |
Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias |
National Cancer Institute / Andre Nussenzweig, Ph.D. |
Reach Grants |
2014 |
Maryland |
Adoptive Immunotherapy of Tr1 Cells to Improve Outcome of Allo-HSCT Treatment for Pediatric AML |
Stanford University / Maria-Grazia Roncarolo, MD & Rosa Bachetta, MD |
Reach Grants |
2015 |
California |
Identification of Rhabdomyosarcoma Therapies Using an Efficient Mouse and Drosophila Repurposing Screen |
Memorial Sloan-Kettering Cancer Center / Mary Baylies, Ph.D. |
Reach Grants |
2014 |
New York |
Targeting PI3Kdelta in Childhood Acute Lymphoblastic Leukemia |
Children’s Hospital Los Angeles / Yong-mi Kim, MD & Nora Heisterkamp, PhD |
Reach Grants |
2015 |
California |
Reversing Feedback Immunosuppression during Oncolytic Virotherapy of Pediatric High Grade Glioma |
Augusta University Research Institute, Inc. / Bangxing Hong, PhD |
Reach Grants |
2023 |
Georgia |